Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 126,600 shares, an increase of 16.4% from the January 15th total of 108,800 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average trading volume […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 108,700 shares, a growth of 12.4% from the October 15th total of 96,700 shares. Approximately 1.1% of the company’s shares are short sold. […]
Cantor Fitzgerald restated their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $4.00 price target on the stock. Cantor Fitzgerald also issued estimates for Lucid Diagnostics’ FY2023 earnings at ($1.14) EPS and FY2024 earnings at ($0.82) EPS. Separately, […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Equities researchers at Cantor Fitzgerald raised their FY2023 EPS estimates for shares of Lucid Diagnostics in a research report issued on Thursday, August 17th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($1.14) for the year, up from their […]
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Tuesday, August 15th. Investors that are interested in participating in the company’s conference call can do so using this link. Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last announced its quarterly earnings results on Monday, […]